In this experiment, the induction of Cd36 and Fabp4 transcription by rosiglitazone was significantly inhibited in both models, suggesting impairment of the Pparg pathway within the stroma of tumor-bearing mammary glands (Fig. 6C). Here, FABP4 is linked to neoplasm.